Harvard Regenerative Reports 402% Q1 Revenue Growth, FDA Approves Phase 1 Trial
HRGN sits 60% above its 52-week low of $0.936.
Summary
Harvard Apparatus Regenerative Technology, Inc. reported significant progress in its first quarter 2026 results, with product revenue surging 402% year-over-year to $226K, alongside an improved net loss of ($1.6M) and diluted EPS of ($0.09). Crucially, the company announced the completion of its first-in-human esophageal implant and received FDA approval for a 10-patient Phase 1 trial, with site activation underway. This clinical advancement is a material positive development, especially given the previous 10-K filing highlighted a "going concern" warning and significant delays in its primary clinical trial. While the company remains unprofitable, these operational and clinical milestones suggest a potential turning point for the highly speculative biotech. Investors will now watch for continued progress in patient recruitment and further clinical trial data.
At the time of this announcement, HRGN was trading at $1.50 on OTC in the Life Sciences sector, with a market capitalization of approximately $26.4M. The 52-week trading range was $0.94 to $5.90. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.